An exclusive worldwide license to develop and commercialize ophthalmology products based on technology from the Schepens Eye Research Institute of Massachusetts Eye and Ear has been obtained by Ocugen, according to a company press release.
The technology, developed by Neena Haider, PhD, associate professor of ophthalmology at Harvard Medical School and associate scientist at Massachusetts Eye and Ear, is a novel modifier gene therapy platform that targets delivery and expression of certain nuclear hormone receptors that are expressed naturally in retinal tissue, the release said.
By regulating
Uncategorized